Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Dexcom

FDA Names Its First Company in a Pilot That Lets Some Digital Health Devices Skip Premarket Review

The FDA selected Dexcom as the first participant in its TEMPO pilot, which pairs relaxed premarket review with real-world evidence collection.

The FDA Just Cleared the First Over-the-Counter Glucose Monitor for Children

The FDA Just Cleared the First Over-the-Counter Glucose Monitor for Children

FDA cleared the first OTC glucose monitor for children ages 2+ on June 12. Here's what this means for families managing prediabetes or Type 2 diabetes.

Earnings Preview: What To Expect From DexCom's Report

Earnings Preview: What To Expect From DexCom's Report

DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

June Brought Two Major FDA Advances for Children with Type 1 Diabetes: Here's What Each One Does

June 2026 brought two FDA milestones for pediatric diabetes: an OTC kids' CGM and teplizumab for Stage 3 Type 1 diabetes in ages 8–17. Here's what each one does and who qualifies.

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

Is DexCom Stock Underperforming the Dow?

DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.

inkl

Read news from The Economist, FT, and more,
with one subscription

The DexCom Stock Turnaround Is Showing Real Signs of Life

The DexCom Stock Turnaround Is Showing Real Signs of Life

DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...

DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement. President and Chief Executive Officer Jake Leach said the company’s next phase

Are Wall Street Analysts Bullish on DexCom’s Stock?

Are Wall Street Analysts Bullish on DexCom’s Stock?

Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects.

Sell in May and Go Away—Starting With These 3 Stocks

Sell in May and Go Away—Starting With These 3 Stocks

Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.

3 Reasons Analysts Love DexCom

3 Reasons Analysts Love DexCom

Continuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market.

DexCom’s Quarterly Earnings Preview: What You Need to Know

DexCom’s Quarterly Earnings Preview: What You Need to Know

DexCom is set to report its first-quarter results at month-end, and the Street is expecting a solid double-digit expansion in earnings.

Is DexCom Stock Underperforming the Nasdaq?

Is DexCom Stock Underperforming the Nasdaq?

DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.

Get all your
news in one place.

100's of premium titles.
One news app.

What Are Wall Street Analysts' Target Price for DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

5 things I hope to see on the Garmin Fenix 9, including the return of a smaller size

The Garmin Fenix 9 could launch later this year and while it’s unlikely to be a major upgrade on the Fenix 8 Pro, I’m hoping to see these five features on a new watch.

Is DexCom Stock Underperforming the S&P 500?

DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom Stock: Is Wall Street Bullish or Bearish?

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL Education Inc (NYSE:TAL), Shake Shack Inc (NYSE:SHAK) and DexCom Inc (NASDAQ:DXCM).

From Dividends to Growth: Why These 3 Stocks Stand Out in 2025

Dividend stocks tend to be stable performers; these companies have a history of recent rallies or the potential to grow in the future.

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

DexCom Earnings Preview: What to Expect

DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside

These two companies could present an opportunity for investors to gain access while they are relatively undervalued and before they appreciate once again.

How Is DexCom's Performance Compared to Other Medical Device Companies?

DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.

1 2 3 4

Organisations

the Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

405,477 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play